Liu Xinyu, Ma Ding, Jing Xiaoqian, Wang Bingrui, Yang Weiping, Qiu Weihua
Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Surgery, No. 197, Ruijin Er Rd., Shanghai, 200025, China.
Med Oncol. 2015 Jan;32(1):392. doi: 10.1007/s12032-014-0392-y. Epub 2014 Dec 5.
Accumulated evidence has indicated a correlation between annexin A2 (ANXA2) and malignancy progression. However, whether ANXA2 expression can be considered as a prognostic factor for cancer patients remains controversial. This meta-analysis aimed to explore the prognostic value of ANXA2 overexpression. A systematically comprehensive search for studies investigating the relationships between ANXA2 expression and outcome of malignant tumor patients was performed using PubMed and EMBASE. Prognostic value of ANXA2 expression in malignancy patients was evaluated regarding overall survival (OS), disease-free survival (DFS) and various clinicopathological features measured by pooled hazard ratios (HRs) or odds ratios and their 95 % confidence intervals (CIs). Fifteen studies including 2,321 patients were enrolled in the meta-analysis. Our results showed that the overexpression of ANXA2 was correlated with poor prognosis in terms of OS (HR 1.56; 95 % CI 1.24-1.97; P < 0.001) and DFS (HR 1.47; 95 % CI 1.18-1.83; P < 0.001) in patients with malignant tumors. In addition, ANXA2 overexpression was significantly associated with tumor invasion (HR 2.06; 95 % CI 1.47-2.89; P < 0.001) and lymph node metastasis (HR 2.25; 95 % CI 1.21-4.15; P = 0.01). However, when age, tumor stage, histological grade and distant metastasis were considered, no obvious association was observed. Publication bias was absent. Sensitivity analysis suggested that the results of this meta-analysis were robust. The present meta-analysis results indicated that ANXA2 overexpression might be associated with poor outcomes in patients with malignant tumors.
越来越多的证据表明膜联蛋白A2（ANXA2）与恶性肿瘤进展之间存在关联。然而，ANXA2表达是否可被视为癌症患者的预后因素仍存在争议。本荟萃分析旨在探讨ANXA2过表达的预后价值。通过PubMed和EMBASE对研究ANXA2表达与恶性肿瘤患者预后关系的研究进行了系统全面的检索。通过合并风险比（HRs）或比值比及其95%置信区间（CIs），评估了ANXA2表达在恶性肿瘤患者中的预后价值，包括总生存期（OS）、无病生存期（DFS）和各种临床病理特征。15项研究共纳入2321例患者进行荟萃分析。我们的结果显示，在恶性肿瘤患者中，ANXA2过表达与OS（HR 1.56；95%CI 1.24 - 1.97；P < 0.001）和DFS（HR 1.47；95%CI 1.18 - 1.83；P < 0.001）方面的预后不良相关。此外，ANXA2过表达与肿瘤侵袭（HR 2.06；95%CI 1.47 - 2.89；P < 0.001）和淋巴结转移（HR 2.25；95%CI 1.21 - 4.15；P = 0.01）显著相关。然而，在考虑年龄、肿瘤分期、组织学分级和远处转移时，未观察到明显关联。不存在发表偏倚。敏感性分析表明本荟萃分析的结果是可靠的。本荟萃分析结果表明，ANXA2过表达可能与恶性肿瘤患者的不良预后相关。
